Bustamante AE, Mascareñas-Martínez L, Fernández LT, González-González GM, Mercado-Longoria R

Language: English
References: 21
Page: 159-164
PDF size: 345.19 Kb.

ABSTRACT

Introduction: Chronic infection with Pseudomonas aeruginosa (P. aeruginosa) is associated with a greater deterioration of pulmonary function, increase in hospitalizations and shorter survival in patients with cystic fibrosis.
Objectives: To evaluate the age of first detection of P. aeruginosa, effectiveness of the eradication treatment and prevalence of other pathogens in airway cultures.
Materials and Methods: A cohort of patients with CF diagnosed within first year of life, who had follow-up at University Hospital was studied. Respiratory cultures were obtained quarterly. Patients with infection by P. aeruginosa received eradication treatment.
Results: Thirty-five patients were included. During follow-up, 608 cultures were performed. In 34.7%, normal flora was detected, S. aureus 32.8%, P. aeruginosa 20.4%. Median age at first positive culture was 9 months. Eradication was achieved in 81.8%.
Conclusions: In this cohort of patients with cystic fibrosis, the acquisition of P. aeruginosa is earlier than in other groups reported in literature.

REFERENCES

1. Salsgiver EL, et al. Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis. Chest 2016;149(2):390-400. DOI: 10.1378/chest.15-0676

2. Pittman JE, et al. Age of Pseudomonas aeruginosa acquisition and subsequent severity of cystic fibrosis lung disease. Pediatr Pulmonol 2011;46(5):497-504. DOI: 10.1002/ppul.21397

3. Li Z, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 20052;293(5):581-8. DOI: 10.1001/jama.293.5.581

4. Lahiri T, et al. Clinical Practice Guidelines From the Cystic Fibrosis Foundation for Preschoolers With Cystic Fibrosis. Pediatrics 2016;137(4). DOI: 10.1542/peds.2015-1784

5. Farrell PM, et al. Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. J Pediatr 2017;181S:S4-S15 e1. DOI: 10.1016/j.jpeds.2016.09.064

6. Lopez-Romo H. Los niveles socioeconomicos y la distribuciòn del gasto. 2009. www.amai.org/NSE/ NivelSocioeconomicoANAI,pdf.

7. Miller MR, et al. Standardisation of spirometry. Eur Respir J 2005;26(2):319-38.

8. Bhalla M, et al. Cystic fibrosis: scoring system with thinsection CT. Radiology 1991;179(3):783-8.

9. Burns JL, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 20011;183(3):444-52. DOI: 10.1086/318075

10. Maselli JH, et al. Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibro sis identified by newborn screening. Pediatr Pulmonol 2003;35(4):257-62. DOI: 10/ppul.10230

11. Rossi GA, et al. Airway microenvironment alterations and pathogen growth in cystic fibrosis. Pediatr Pulmonol 2019;54(4):497-506. DOI: 10.1002/ppul.10230

12. Abman SH, et al. Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening. J Pediatr 1991;119(2):211-7. DOI: 10.1016/s0022-3476(05)80729-2

13. D'Alessandro V, et al. [Comparing the clinical-functional state in children with cystic fibrosis detected by neonatal screening or by clinical symptoms]. Arch Argent Pediatr 2009;107(5):430-5. DOI: 10.1590/S0325- 00752009000500010

14. Douglas TA, et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J 2009;33(2):305-11. DOI: 10.1183/09031936.00043108.

15. Psoter KJ, et al. Season is associated with Pseudomonas aeruginosa acquisition in young children with cystic fibrosis. Clin Microbiol Infect 2013;19(11):E483-9. DOI: 10.1111/1469-0691.12272.

16. 2019 [updated 05/05/2019; consultado; Disponible en: https://www.weather-mx.com/es/mexico/monterrey-clima.

17. Collaco JM, et al. Effect of temperature on cystic fibrosis lung disease and infections: a replicated cohort study. PLoS One 2011;6(11):e27784. DOI: 10.1371/journal. pone.0027784

18. Sanchez-Dominguez CN, et al. Low-income status is an important risk factor in North East Mexican patients with cystic fibrosis. Rev Invest Clin 2014;66(2):129-35.

19. Rho J, et al. Disparities in Mortality of Hispanic Patients with Cystic Fibrosis in the United States. A National and Regional Cohort Study. Am J Respir Crit Care Med 201815;198(8):1055- 63. DOI: 10.1164/rccm.201711-2357OC

20. Buu MC, et al. Assessing Differences in Mortality Rates and Risk Factors Between Hispanic and Non-Hispanic Patients With Cystic Fibrosis in California. Chest 2016;149(2):380-9. DOI: 10.1378/chest.14-2189

21. Psoter KJ, et al. Fine particulate matter exposure and initial Pseudomonas aeruginosa acquisition in cystic fibrosis. Ann Am Thorac Soc 2015;12(3):385-91. DOI: 10.1513/ AnnalsATS.201408-400OC